Merck has struck a major multi-year partnership with Google Cloud worth up to $1 billion, aimed at transforming the pharmaceutical giant into a fully AI-enabled enterprise.
The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations. Google Cloud engineers will embed directly with Merck teams to deploy advanced AI systems, including Gemini Enterprise, as part of a deep integration strategy spanning the company’s global workforce of 75,000 employees.
The move is designed to accelerate drug development, streamline operations, and embed AI-driven decision-making across the entire pharma value chain—positioning both companies at the center of the next wave of biopharmaceutical innovation.
“Merck’s collaboration with Google Cloud represents the next phase of our AI journey, extending our longstanding use of advanced technologies into an intelligent agentic ecosystem that will work alongside our teams as we enter one of the most significant launch periods in our company’s history,” said Dave Williams, chief information and digital officer, Merck.
“AI agents and generative tools will help our teams around the world reimagine processes at scale and bring scientific breakthroughs to patients faster.”
Google Cloud framed the deal as a structural shift in how artificial intelligence reshapes drug development and healthcare operations.
“Our partnership with Merck represents a fundamental shift in how technology supports the entire pharma value chain,” said Thomas Kurian, CEO, Google Cloud.
“By deploying an industry-first agentic ecosystem powered by Gemini Enterprise, Merck is not just optimizing business processes; it is building a future where the speed of AI and the expertise of human ingenuity come together to bring drugs to patients faster and solve problems that were previously out of reach.”
Under the partnership, Merck will build AI systems on Google Cloud to accelerate R&D workflows, enhance manufacturing through predictive analytics and automation, and personalize commercial and patient engagement using data-driven insights. Corporate functions will also be overhauled with AI-powered automation to boost productivity.
Together, the companies are betting big on an AI-first model for pharma—one designed to compress timelines, unlock scientific discovery, and reshape how medicines reach patients worldwide.
